Inventiva Pharmaare a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with significant unmet medical needs in the are
as of fibrosis, lysosomal storage disorders and oncology. We have built a pipeline backed by a discovery engine with an extensive library of proprietary molecules, a wholly-owned research and development facility and a team with significant expertise and deep experience in the development of compounds that target nuclear receptors, transcription factors and epigenetic modulation. By leveraging these assets and expertise, we are advancing two clinical candidates in two indications, as well as
LikeShareFollow
| Inventiva Pharma |
| Inventiva Pharmaare a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with significant unmet medical needs in the areas of fibrosis, lysosomal storage disorders and oncology. We have built a pipeline backed by a discovery engine with an extensive library of proprietary molecules, a wholly-owned research and development facility and a team with significant expertise and deep experience in the development of compounds that target nuclear receptors, transcription factors and epigenetic modulation. By leveraging these assets and expertise, we are advancing two clinical candidates in two indications, as well as a deep pipeline of earlier stage programs. |
| Inventiva Pharmaare a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with significant unmet medical needs in the areas of fibrosis, lysosomal storage disorders and oncology. We have built a pipeline backed by a discovery engine with an extensive library of proprietary molecules, a wholly-owned research and development facility and a team with significant expertise and deep experience in the development of compounds that target nuclear receptors, transcription factors and epigenetic modulation. By leveraging these assets and expertise, we are advancing two clinical candidates in two indications, as well as a deep pipeline of earlier stage programs. |
Trusted Seller
| ||||||||||
